Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study
Maud Velev, Cécile Dalban, Christine Chevreau, Gwénaëlle Gravis, Sylvie Négrier, Brigitte Laguerre, Marine Gross‐Goupil, Sylvain Ladoire, Delphine Borchiellini, Lionnel Geoffrois, Florence Joly, Frank Priou, Philippe Barthélémy, Mathieu Laramas, Berangère Narciso, Antoine Thiery-Vuillemin, Jean-François Berdah, Victoria Ferrari, Quentin Dominique Thomas, Cécile Mione, Hubert Curcio, Stéphane Oudard, Florence Tantot, Bernard Escudier, Sylvie Chabaud, Laurence Albigès, Constance Thibault
Topics & Concepts
Renal cell carcinomaNivolumabMedicineOncologyPhases of clinical researchInternal medicineCancerImmunotherapyToxicityRenal cell carcinoma treatmentManagement of metastatic bone diseaseCancer Immunotherapy and Biomarkers